Conclusions
- RCC1 expression is a negative prognostic marker in NSCLC, PC, and CRC
- Further studies to investigate this at the molecular level may be a potential opportunity for novel targeted drug development
Innovation
Publications
Multiomic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes
– Caris Life Sciences